Hannover, Germany, 09 March 2018 – iF International Forum Design GmbH has recognized Octane’s Cocoon technology with this year’s iF Design Award for best product – a tremendous honour from one of the world’s most celebrated and valued design competitions, with more than 6,000 submissions each year from about 70 countries.
“The iF Design Award is recognized as a symbol of design excellence around the world,” says Octane CEO Tim Smith. “This international aspect makes this award especially meaningful for all of us at Octane.”
Cocoon is an automated bioreactor that enables production scale-up of cell and tissue engineering for clinical cell therapy and tissue regeneration. Current manual processes for growing human cells and tissues are time-consuming, inefficient and potentially prone to contamination. With Cocoon, these processes are transformed into automated programs that produce breakthrough, patient-specific treatments that are economical, safe and commercially scalable.
“Combined with our innovations in cell therapy and tissue engineering, Cocoon is advancing our vision of regenerative medicine as the standard of care,” says Smith.
For press inquiries please contact Renee Thibodeau
Recognized as a symbol of design excellence around the world, the iF Design Award welcomes over 6,000 submissions from 70 countries every year. Since 1953, iF has followed the following principles: To identify, support and promote good design; Raise awareness of design among the public and the role it plays in our lives; To help companies integrate design into their long-term strategies; To safeguard the role of professional design and boost awareness of this job profile; To affect social change through design, and; To support talented young people and create a public platform for young designers.
Cocoon™ is a patient-scale cell therapy system that forms the core of a series of versatile cell and tissue therapy production systems. Unlike other bioreactor systems, this platform integrates multiple steps, including upstream and downstream processing. From cell source isolation and cell expansion, through to cell collection, cell washing and final product formation – all in a closed, single-use disposable cassette
Coupled with advanced bioreactors, biosensor feedback and innovative cell scaffolds, this cell culture and tissue engineering platform opens up an array of clinical applications. Cocoon is an integrated turnkey production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please read more about our game-changing innovations in regenerative medicine.
Kingston, Ontario, June 2, 2022 – Octane Exo Inc., an Octane Medical Group venture, has achieved a breakthrough in medical implant technology with Octane HyperPEEK, an advanced biocomposite proven to enhance bone regeneration with the goal of enhanced integration and stability.
March 2, 2022
Kingston, Ontario, 15 December 2020 – Octane Medical Group has expanded its state-of-the-art facility in Kingston, Ontario Canada. The 40,000-square-foot building, which Octane purchased in 2011, houses the company's head office and features regulated biolabs for biomaterial and biologics discovery programs including cell therapy research and development, a ...
December 15, 2020
Maine, USA, 18 March 2020 – Octane innovations in tissue engineering, personalized medicine and automated living implant production have earned one of the highest Edison Awards, winning Gold in the Medical / Dental Cellular Research category. The Gold award recognizes AUTOGRAFTA™ living graft technology and the ability to ...
March 18, 2020
Basel, Switzerland, 29 October 2018 – Lonza announced today the acquisition of a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane ...
October 29, 2018